LB08 - Secondary factors in chronic lymphocytic leukemia (CLL) such as COBBLL1 and response prediction in TP53 non-mutant cohort treated with single agent venetoclax or Obinutuzumab

Primary Author / Presenter(s)

Maher Salamoon, Sr., MD

Consultant hematology/oncology
Al Bairouni University Cancer Center
Damascus, Dimashq, Syria